Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
06/2012
06/28/2012WO2012087236A1 Compounds and their use as bace inhibitors
06/28/2012WO2012087229A1 2-carboxamide-4-piperazinyl-benzofuran derivative
06/28/2012WO2012087180A1 Method for treating acute cerebral and spinal blood flow disorders of an ischaemic or haemorrhagic nature
06/28/2012WO2012087047A2 Percutaneous absorption preparation containing rivastigmine
06/28/2012WO2012086853A1 Composition for positively allosterically modulating gabaa-benzodiazepine receptor and composition for producing sedative-hypnotic effects containing ecklonia cava extract and ecklonia kurome extract
06/28/2012WO2012086712A1 Elution-controlled oral liquid preparation
06/28/2012WO2012086474A1 Therapeutic agent for central nervous system diseases
06/28/2012WO2012086428A1 Medicinal composition comprising calmodulin-like skin protein as active ingredient
06/28/2012WO2012086157A1 Method of intensifying the physiological action of caffeine
06/28/2012WO2012085954A1 Combination comprising d-apartic acid and l-arginine or salts thereof for the improvement of cognitive activities and memory in dementia such as dementia senile and alzheimer's disease
06/28/2012WO2012085857A1 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides
06/28/2012WO2012085852A1 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides
06/28/2012WO2012085721A1 Novel fused pyridine compounds as casein kinase inhibitors
06/28/2012WO2012085650A1 Substituted pyridines as sodium channel blockers
06/28/2012WO2012085648A1 Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
06/28/2012WO2012085244A1 Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
06/28/2012WO2012085166A1 Metabotropic glutamate receptor modulators
06/28/2012WO2012085038A1 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
06/28/2012WO2012084999A1 Prokineticin 1 receptor agonists and their uses
06/28/2012WO2012084976A1 Novel multicomponent crystals made of ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester and an arylpropionic acid
06/28/2012WO2012084975A1 Novel multicomponent crystals made of ([2-amino-6-(4-fluoro-benzylamino)- pyridin-3-yl]-carbamic acid ethyl ester and 2-[2-[(2,6-dichlorphenyl)-amino]-phenyl]-acetic acid
06/28/2012WO2012084873A1 4- (hetero) aryl - ethynyl - octahydro - indole - 1 - carboxylic acid esters
06/28/2012WO2012084126A2 Formulation of lacosamide
06/28/2012WO2012083493A1 Medicinal composition
06/28/2012WO2012061289A9 Methods for treatment of brain injury utilizing biologics
06/28/2012WO2012049222A3 Novel omega-3 and omega-6 fatty acid compositions and uses thereof
06/28/2012WO2012040444A3 Treatment of patients with incipient alzheimer's disease
06/28/2012WO2012039578A3 Composition for preventing and treating amyloid diseases, comprising cyclophilin b
06/28/2012WO2012037397A3 Step-derived peptide for brain injury treatment
06/28/2012WO2012036433A3 Treatment of neurodegenerative diseases by targeting mirna
06/28/2012WO2012033329A3 Composition containing oenanthe javanica extract as an active ingredient for preventing or treating learning disabilities or memory disorders, and method for preparing same
06/28/2012WO2011156786A8 6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
06/28/2012WO2011154725A3 Compositions comprising buprenorphine
06/28/2012WO2011135464A3 N-(aminoacyl)-amino compound
06/28/2012US20120167240 Compositions and Methods for Modulating PGC-1Alpha to Treat Neurological Diseases and Disorders
06/28/2012US20120165412 Use of Resveratrol or Another Hydroxylated Stilbene For Preserving Cognitive Functioning
06/28/2012US20120165406 Bis-trifluoromethyl honokiol analogs and their use in treating cancers
06/28/2012US20120165405 Anaplerotic Therapy of Huntington Disease and Other Polyglutamine Diseases
06/28/2012US20120165404 Treatment of neurodegeneration and neuroinflammation
06/28/2012US20120165402 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
06/28/2012US20120165388 Fatty acid binding proteins as drug targets for endocannabinoids
06/28/2012US20120165382 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
06/28/2012US20120165380 Methods of treating alpha adrenergic mediated conditions
06/28/2012US20120165378 Thiophene-carboxamides useful as inhibitors of protein kinases
06/28/2012US20120165372 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
06/28/2012US20120165368 Pyrazolopyridine kinase inhibitors
06/28/2012US20120165367 Azaindazoles useful as inhibitors of kinases
06/28/2012US20120165363 Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders
06/28/2012US20120165362 Androgen receptor modulator compounds and methods
06/28/2012US20120165361 Drug coating providing high drug loading and methods for providing the same
06/28/2012US20120165360 Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
06/28/2012US20120165359 Opioid Agonist/Antagonist Combinations
06/28/2012US20120165358 Controlled release formulations of opioid and nonopioid analgesics
06/28/2012US20120165349 Phenyl-Substituted Pyrazolopyrimidines
06/28/2012US20120165347 Compounds and their use as BACE Inhibitors
06/28/2012US20120165346 Compounds and their use as BACE inhibitors
06/28/2012US20120165341 Therapeutic agent for senile dementia
06/28/2012US20120165339 Cyclopropane derivatives
06/28/2012US20120165337 Tetrahydroquinoxaline urea derivatives, preparation thereof, and therapeutic use thereof
06/28/2012US20120165336 Color Change Time Indicator for Packaging System
06/28/2012US20120165331 Di/tri-aza-spiro-C9-C11alkanes
06/28/2012US20120165330 Quinazolinone and related analogs as sirtuin modulators
06/28/2012US20120165329 Compounds and methods for kinase modulation, and indications therefor
06/28/2012US20120165326 Derivatives of 6-(6-substituted-triazolopyridazine-sulfanyl) 5-fluoro benzothiazoles and 5-fluoro benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
06/28/2012US20120165325 Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
06/28/2012US20120165322 Rho kinase inhibitors
06/28/2012US20120165321 Quinoline derivatives as pi3 kinase inhibitors
06/28/2012US20120165320 Novel azabicyclohexanes
06/28/2012US20120165319 Inhibitors of interleukin-1 beta converting enzyme
06/28/2012US20120165315 Meptazinol carbamate prodrug salts
06/28/2012US20120165311 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
06/28/2012US20120165307 Azaindoles useful as inhibitors of janus kinases
06/28/2012US20120165304 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
06/28/2012US20120165303 Triazolyl phenyl benzenesulfonamides
06/28/2012US20120165300 Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
06/28/2012US20120165294 4,5-dihydro-oxazol-2yl derivatives
06/28/2012US20120165293 Synthesis of prostanoids
06/28/2012US20120165292 METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE
06/28/2012US20120165285 Combined preparation for use as a medicament
06/28/2012US20120165281 Stilbenoid derivatives and their uses
06/28/2012US20120165277 Novel galactoside inhibitors of galectins
06/28/2012US20120165267 Apo-2 LIGAND/TRAIL VARIANTS AND USES THEREOF
06/28/2012US20120165266 Method for preparing gintonin, which is a novel glycolipoproetin from panax ginseng, and gintonin, which is a novel glycolipoprotein, prepared by the method
06/28/2012US20120165259 Agent for ameliorating blood-brain barrier disorders
06/28/2012US20120165256 Use of erythropoietin and substances increasing and/or prolonging the activation and/or stimulation of erythropoietin receptors for treating and/or preventing schizophrenia and related psychoses
06/28/2012US20120165251 Diabetes therapy
06/28/2012US20120164247 Medicinal and herbal composition and uses thereof
06/28/2012US20120164245 Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same
06/28/2012US20120164243 Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders
06/28/2012US20120164229 Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
06/28/2012US20120164228 Novel pharmaceutical formulations to prevent the misuse of medicinal drugs
06/28/2012US20120164226 Compositions and Methods for Improving Prognosis of a Human with Subarachnoid Hemorrhage
06/28/2012US20120164220 Encased Tamper Resistant Controlled Release Dosage Forms
06/28/2012US20120164218 Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
06/28/2012US20120164216 Pharmaceutical composition of duloxetine or pharmaceutically
06/28/2012US20120164209 Abuse resistant drugs, method of use and method of making
06/28/2012US20120164207 Degradable networks for sustained release and controlled release depot drug delivery applications
06/28/2012US20120164191 Transmucosal delivery devices with enhanced uptake
06/28/2012US20120164188 Paliperidone or a pharmaceutically acceptable salt thereof substantially free of impurities
06/28/2012US20120164161 Antibodies and Uses Thereof
1 ... 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 ... 1833